EpiVax, Inc.

EpiVax, Inc. is a biotechnology firm specializing in immunogenicity assessment and sequence optimization for biologic therapeutics and vaccines, providing essential tools to enhance safety and efficacy in drug development. Founded in 1998 and headquartered in Providence, US, EpiVax, Inc. focuses on immunogenicity assessment for biologics.

The company has pivoted over the years to refine its strategies in biologics and vaccine development. Co-founders Annie De Groot and Mohammed Ramley have led the firm through significant milestones, including raising USD 0. 6 million in GRANT funding in September 2016 from the National Institutes of Health, which reflects its ongoing commitment to advancing immunology research. EpiVax has completed a total of 9 deals since its inception.

EpiVax specializes in immunogenicity assessment and sequence optimization for biologic therapeutics and vaccines. The company's core offerings include a suite of proprietary in silico and in vitro techniques for T cell epitope identification, such as the ISPRI™ suite, which provides comprehensive analyses to optimize immunogenicity while enhancing product safety and efficacy. EpiVax serves 18 of the 20 largest pharmaceutical companies and collaborates with over 500 clients from academia, industry, and regulatory bodies globally, addressing the demand for effective biologic therapies and vaccines. EpiVax generates revenue primarily through consulting services and contracted projects with pharmaceutical and biotech companies.

Engaging in B2B transactions, the firm offers immunogenicity assessment and optimization services through tailored agreements, which may include project-based and ongoing partnerships. Collaborations often begin with clients selecting specific services from EpiVax’s comprehensive offerings and may lead to multi-year contracts, incorporating fixed fees or milestone-based payments to ensure detailed reporting and insights throughout product development processes. EpiVax plans to leverage its recent GRANT funding of USD 0. 6 million to expand its product offerings and enhance its service capabilities.

The company is designing new products aimed at improving immunogenicity assessment techniques, with plans for release in the next 18 months. Additionally, EpiVax targets expansion into key markets in Asia and Europe by late 2024, aiming to establish new partnerships and collaborations that will further solidify its presence in the global biotechnological landscape.